Aspirin as an antithrombotic drug: from the aggregometer to clinical trials.
de Gaetano G·Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie
Aspirin inhibits thromboxane A2 and prostaglandin formation in platelets and prostaglandin I2 (prostacyclin) in vascular cells. It prevents platelet aggregation by irreversible acetylation of cyclooxygenase, a key enzyme in the arachidonic acid metabolism. Oral aspirin can be extensively hydrolyzed to inactive salicyla…